Researchers in South Korea have proposed a novel cancer immunotherapy approach that could complement existing CAR-T (Chimeric Antigen Receptor T-cell) treatments.

Negative Breast Cancer Market Insight, Epidemiology and Market Forecast - 2035" report delivers comprehensive insights into triple-negative breast cancer, i ...

Single-cell RNA sequencing (scRNA-seq) has confirmed that MM exhibits high intra-tumor heterogeneity, comprising a mixture of ...

Discover comprehensive insights into approved therapeutics and research developments targeting Prostate-Specific Membrane Antigen (PSMA). This product provides detailed competitor analysis, R&D stages ...

"Anti-GPRC5D CAR T-cell salvage therapy induced a high response rate and might be a potential treatment option in patients with relapsed or refractory multiple myeloma who had pro ...

Compromised antigen presentation ranks among the top mechanisms that render cancers non-immunogenic (non-responsive to immune ...

A newly developed radiolabeled antibody that targets the cancer antigen IL13Rα2 has been found to be highly specific, binding ...

More than five years have passed since the arrival in Italy of the first anti -cancer gene therapy, the Car-t ...

Immunome's strong financial position supports ongoing clinical development and potential market entry for key assets. See why ...

Researchers have developed novel lymph-node-inspired hydrogels that significantly enhance the activation, gene expression, ...

In a live virtual event, Thomas C. Krivak, MD, reviewed the key studies of PARP inhibitor and bevacizumab maintenance in ...

In particular, T-cell engager bsAbs facilitate immune cell–mediated tumor destruction by linking T cells to tumor antigens. Instead, dual immune checkpoint inhibitors (CPIs) enhance immune activation ...